Mark Murcko, Ph.D.

Dr. Murcko, Principal at Disruptive Biomedical, LLC is an independent consultant and Professor of Practice at both MIT and Northeastern. Until November 2011, he was Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals. In the former role, he was responsible for the identification, validation and incorporation of disruptive technologies across global R&D. Dr. Murcko is a co-inventor of Incivek™ (telaprevir), the world’s most widely prescribed HCV protease inhibitor, Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex’s two marketed drugs for HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that produced the marketed drug Kalydeco® (ivacaftor) and several other compounds currently in late stage development.

Dr. Murcko is also a co-inventor of eight clinical candidates in the areas of cancer, inflammation/immunology and infectious disease. Prior to Vertex, Dr. Murcko worked at Merck Sharp & Dohme. He has served on the editorial boards of many scientific publications, was the co-organizer of the 2008 ACS National Medicinal Chemistry Symposium, and served as Chair of the 2013 Gordon Research Conference in Medicinal Chemistry. He is a co-inventor on more than 45 issued patents, has co-authored more than 85 scientific articles, and has delivered more than 130 invited lectures.